Search
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … [A254726,L44256] Other IDH1 inhibitors, such as [ivosidenib], have also been approved for the treatment of relapsed or refractory AML.
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsIONIS-FGFR4Rx
go.drugbank.com/drugs/DB16198InvestigationalIONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).
Lactitol
go.drugbank.com/drugs/DB12942Approved[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in
Categories: Drugs for ConstipationEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.
Categories: P-glycoprotein substratesGlutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalA tripeptide with many roles in cells. … It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Aclidinium
go.drugbank.com/drugs/DB08897ApprovedAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD).
Categories: Drugs for Obstructive Airway DiseasesBeremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigationalDeveloped by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.
Categories: Preparations for Treatment of Wounds and UlcersPhenoxymethylpenicillin
go.drugbank.com/drugs/DB00417ApprovedInvestigationalVet approvedsurgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis. … as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and
Synonyms: PVCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigational[A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions … Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNorgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigational[A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.
Categories: Hormonal Contraceptives for Systemic Use, P-glycoprotein inhibitors